Most-Downgraded StocksMost-DowngradedNASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $37.86 -0.75 (-1.93%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Sarepta Therapeutics Stock (NASDAQ:SRPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sarepta Therapeutics alerts:Sign Up Key Stats Today's Range$36.96▼$38.1350-Day Range$35.27▼$73.6152-Week Range$34.10▼$173.25Volume445,502 shsAverage Volume1.80 million shsMarket Capitalization$3.72 billionP/E Ratio30.32Dividend YieldN/APrice Target$122.61Consensus RatingModerate Buy Company OverviewSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More… Sarepta Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreSRPT MarketRank™: Sarepta Therapeutics scored higher than 96% of companies evaluated by MarketBeat, and ranked 56th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 17 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth309.74% Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 309.74% in the coming year, from $2.67 to $10.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 30.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.20.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 30.89, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.02% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 31.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.65 Percentage of Shares Shorted10.02% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 31.79%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.64 News SentimentSarepta Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Sarepta Therapeutics this week, compared to 14 articles on an average week.Search Interest95 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 188% compared to the previous 30 days.MarketBeat Follows14 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $248,203.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Stock News HeadlinesPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore (SRPT)These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and nextMay 14, 2025 | marketbeat.comResearch Analysts Set Expectations for SRPT Q2 EarningsMay 30 at 1:18 AM | americanbankingnews.comElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.May 30, 2025 | Colonial Metals (Ad)Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?May 27 at 10:37 AM | insidermonkey.comHC Wainwright Reaffirms "Neutral" Rating for Sarepta Therapeutics (NASDAQ:SRPT)May 25, 2025 | americanbankingnews.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comJPMorgan Chase & Co. Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $84.00May 23, 2025 | americanbankingnews.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $121.59 on January 1st, 2025. Since then, SRPT stock has decreased by 68.2% and is now trading at $38.61. View the best growth stocks for 2025 here. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its earnings results on Tuesday, May, 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by $5.62. The firm's revenue for the quarter was up 80.2% compared to the same quarter last year. Read the conference call transcript. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional investors include Vanguard Group Inc. (9.19%), Wellington Management Group LLP (2.69%), T. Rowe Price Investment Management Inc. (2.03%) and EcoR1 Capital LLC (1.32%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Claude Nicaise, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Stephen Mayo and Kathryn Jean Boor. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN). Company Calendar Last Earnings5/06/2025Today5/30/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees840Year Founded1980Price Target and Rating Average Stock Price Target$122.61 High Stock Price Target$230.00 Low Stock Price Target$40.00 Potential Upside/Downside+217.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)($2.69) Trailing P/E Ratio30.89 Forward P/E Ratio14.46 P/E GrowthN/ANet Income-$535.98 million Net Margins7.43% Pretax Margin7.89% Return on Equity11.00% Return on Assets3.35% Debt Debt-to-Equity Ratio0.93 Current Ratio3.84 Quick Ratio3.03 Sales & Book Value Annual Sales$2.23 billion Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book4.20Miscellaneous Outstanding Shares98,277,000Free Float88,165,000Market Cap$3.79 billion OptionableOptionable Beta0.85 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:SRPT) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.